Rezolute, Inc. (RZLT)
NASDAQ:RZLT
Want to see RZLT full AI Analyst Report?
Top Page
Rezolute
(NASDAQ:RZLT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$4.50
▲(30.06% Upside)
Action:Reiterated
Date:06/04/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and increasing cash burn), partly offset by a low-debt balance sheet. Technicals are constructive but overbought, and recent positive Phase 3 and FDA-interaction updates improve the outlook despite valuation being constrained by losses.
Positive Factors
Positive interim Phase 3 upLIFT data for ersodetug
Robust interim efficacy and tolerability in a severe, unmet tumor hyperinsulinism population establishes clinical proof-of-concept for ersodetug. Durable clinical signal plus patient continuation to long-term extension strengthens the case for regulatory filings, partnerships, and downstream commercial potential.
Negative Factors
No commercial revenue; widening net losses
Persistent pre-revenue status and expanding losses mean the company lacks internal cash generation to fund operations long-term. Structural unprofitability increases reliance on external capital, raises dilution risk for shareholders, and constrains investment flexibility for pipeline expansion or commercialization build-out.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive interim Phase 3 upLIFT data for ersodetug
Robust interim efficacy and tolerability in a severe, unmet tumor hyperinsulinism population establishes clinical proof-of-concept for ersodetug. Durable clinical signal plus patient continuation to long-term extension strengthens the case for regulatory filings, partnerships, and downstream commercial potential.
Read all positive factors
Rezolute (RZLT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$434.28M
Dividend YieldN/A
Average Volume (3M)1.65M
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue GrowthN/A
EPS Growth29.97%
CountryUS
Employees64
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.82
Shares Outstanding96,292,330
10 Day Avg. Volume2,174,926
30 Day Avg. Volume1,651,309
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-13.38K
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$8.00Price Target Upside131.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Rezolute Business Overview & Revenue Model
Company Description
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal ...
How the Company Makes Money
Rezolute does not have a broadly disclosed, established commercial revenue stream from marketed products; as a clinical-stage biotech, its operations are primarily funded through external financing rather than recurring product revenue. Primary so...
Rezolute Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -23.00K | 0.00 | 0.00 | 0.00 | 0.00 | -13.00K |
| EBITDA | -85.56M | -79.86M | -70.39M | -55.96M | -39.24M | -20.51M |
| Net Income | -81.48M | -74.41M | -68.46M | -51.79M | -41.06M | -20.90M |
Balance Sheet | ||||||
| Total Assets | 125.46M | 175.49M | 132.74M | 123.72M | 152.42M | 42.61M |
| Cash, Cash Equivalents and Short-Term Investments | 120.27M | 167.86M | 126.87M | 101.90M | 150.41M | 41.05M |
| Total Debt | 1.11M | 1.61M | 2.23M | 2.48M | 188.00K | 14.42M |
| Total Liabilities | 8.63M | 13.36M | 11.73M | 7.55M | 2.95M | 16.51M |
| Stockholders Equity | 116.83M | 162.13M | 121.00M | 116.17M | 149.47M | 26.10M |
Cash Flow | ||||||
| Free Cash Flow | -73.48M | -69.08M | -57.37M | -44.63M | -39.62M | -20.44M |
| Operating Cash Flow | -73.48M | -69.08M | -57.37M | -44.48M | -39.62M | -20.44M |
| Investing Cash Flow | -33.05M | -14.54M | 48.70M | -101.46M | 0.00 | 0.00 |
| Financing Cash Flow | 103.17M | 107.33M | 63.03M | 11.57M | 148.98M | 51.53M |
Rezolute Technical Analysis
Positive
3.46
Price Trends
3.37
Positive
3.24
Positive
5.34
Negative
Market Momentum
0.26
Negative
67.33
Neutral
84.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RZLT, the sentiment is Positive. The current price of 3.46 is below the 20-day moving average (MA) of 3.50, above the 50-day MA of 3.37, and below the 200-day MA of 5.34, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 67.33 is Neutral, neither overbought nor oversold. The STOCH value of 84.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RZLT.
Rezolute Risk Analysis
Rezolute disclosed 31 risk factors in its most recent earnings report. Rezolute reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rezolute Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $859.29M | 5.12 | 129.32% | ― | 2889.93% | ― | |
56 Neutral | $434.28M | ― | -58.82% | ― | ― | 29.97% | |
56 Neutral | $1.69B | -15.53 | -56.07% | ― | 3.42% | -11.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $776.24M | -11.25 | -28.90% | ― | 68.64% | 50.57% | |
48 Neutral | $2.14B | -8.33 | -253.85% | ― | ― | -15.28% | |
47 Neutral | $846.70M | ― | -28.77% | ― | -23.48% | 25.73% |
* Healthcare Sector Average
RZLT
Rezolute
4.25
-0.18
-4.06%
GERN
Geron
1.17
-0.43
-26.88%
ABUS
Arbutus Biopharma
4.25
0.77
22.13%
XNCR
Xencor
11.77
2.12
21.97%
KOD
Kodiak Sciences
31.05
26.83
635.78%
TSHA
Taysha Gene Therapies
5.50
2.66
93.66%
Rezolute Corporate Events
Business Operations and StrategyProduct-Related Announcements
Rezolute Reports Positive Phase 3 Data for Ersodetug
Positive
Jun 2, 2026
On June 2, 2026, Rezolute reported positive interim data from its open-label Phase 3 upLIFT trial evaluating ersodetug in tumor hyperinsulinism, a rare and severe cause of hypoglycemia linked to insulinoma and non-islet cell tumors. The company ha...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Rezolute Shares Expanded Phase 3 sunRIZE Data With FDA
Positive
May 4, 2026
On May 1, 2026, Rezolute announced expanded Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism, presented at the Pediatric Endocrine Society 2026 meeting, showing consistent, clinically meaningful improvements in continuous glucose m...
Business Operations and StrategyRegulatory Filings and Compliance
Rezolute Prepares FDA Submission After sunRIZE Trial Review
Neutral
Mar 24, 2026
On March 24, 2026, Rezolute reported outcomes from a March 17 in-person Type B FDA meeting regarding sunRIZE, its Phase 3 trial of ersodetug in congenital hyperinsulinism, after the study previously failed to meet its primary endpoint in December ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.